Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

Components of
Polio Vaccine

Excipients Table
Allergens Table
Components Table

 

Indication

Immunization against polio-virus types 1, 2, and 3

Proprietary Name

IPOL

Manufacturers

sanofi pasteur

Viability

Inactivated

Microorganism

Single stranded RNA polio virus genus Enterovirus

Ages

6 weeks of age and older

Dose

0.5 mL

Route

Intramuscular or subcutaneous

Dose form

Suspension

Appearance

Clear and Colorless

Concentration (per 0.5 mL)

Type 1 Poliovirus, 40 D antigen units

Type 2 Poliovirus, 8 D antigen units

Type 3 Poliovirus, 32 D antigen units

Preservatives

2-phenoxyethanol, 0.5%

Formaldehyde, 0.02%

Adjuvants

None

Excipients

Calf serum from bovine spongiform encephalopathy free countries, <1 ppm

Allergens

Neomycin,<5 ng

Streptomycin, 200 ng

Polymyxin, 25 ng

Media

Vero cells from monkey kidney cells of Vervet or African green monkeys.

Grown in Eagle MEM modified medium.

For viral growth the culture medium is replaced by M-199 without calf serum.

Packaging

Syringe, without needle (10 per pack)

10-dose vial

Routine storage

2 to 8 C (35-46 F)

Do not freeze; protect from light

Package Insert last updated

October 2012

updated June 2013

This page was last updated on February 12, 2014

2014 Institute for Vaccine Safety